Menu
Recruiting NCT06810375

Erector Spinae Versus Intercostal Nerve Blocks With Liposomal Bupivacaine for Analgesia in Thoracic Surgery

Phase III Interventional Lung Cancers

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Erector Spinae (ESP) Block with Bupivacaine (Marcaine®), Intercostal nerve block.
Who it may be relevant to
Registry conditions: Lung Cancers. Basic parameters: 18 years — 90 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

This clinical trial compares efficacy in postoperative pain management in thoracic surgery between erector spinae block versus liposomal bupivacaine injections.

Interventions

  • Drug Erector Spinae (ESP) Block with Bupivacaine (Marcaine®)
    preoperative erector spinae block with bupivacaine (Marcaine®)
  • Drug Intercostal nerve block
    intraoperative intercostal nerve block with liposomal bupivacaine (Exparel®)

Primary outcome measures

  • Postoperative pain control assessment [Time frame: Up to 48 hours postoperatively]
  • Morphine equivalent assessment [Time frame: Up to 72 hours postoperatively]
Secondary outcome measures (1)
  • Postoperative pain control assessment [Time frame: Up to 72 hours postoperatively]

Eligibility criteria

Inclusion criteria

  • Video assisted pulmonary resection, pleurodesis or decortication

Exclusion criteria

  • Allergy to local anesthetics
  • Patient undergoing bilateral surgery
  • Surgery is emergent as deemed by the principal investigator

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Treatment

Study locations

United States · 1 center
  • The George Washington University Hospital — Washington D.C.

Identifiers

NCT: NCT06810375 · NCR246143

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗